NI201400107A - Compuestos de heterociclilo como inhibidores de mek - Google Patents
Compuestos de heterociclilo como inhibidores de mekInfo
- Publication number
- NI201400107A NI201400107A NI201400107A NI201400107A NI201400107A NI 201400107 A NI201400107 A NI 201400107A NI 201400107 A NI201400107 A NI 201400107A NI 201400107 A NI201400107 A NI 201400107A NI 201400107 A NI201400107 A NI 201400107A
- Authority
- NI
- Nicaragua
- Prior art keywords
- compounds
- mek inhibitors
- heterocyclyl compounds
- formula
- present
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title abstract 4
- 239000002829 mitogen activated protein kinase inhibitor Substances 0.000 title abstract 2
- 125000001072 heteroaryl group Chemical group 0.000 abstract 2
- 238000000034 method Methods 0.000 abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K31/541—Non-condensed thiazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N5/00—Radiation therapy
- A61N5/10—X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Biomedical Technology (AREA)
- Oncology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Hematology (AREA)
- Cardiology (AREA)
- Communicable Diseases (AREA)
- Rheumatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Heart & Thoracic Surgery (AREA)
- Radiology & Medical Imaging (AREA)
- Pathology (AREA)
- Diabetes (AREA)
- Dermatology (AREA)
- Hospice & Palliative Care (AREA)
- Obesity (AREA)
- Pulmonology (AREA)
- Vascular Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Psychiatry (AREA)
- Urology & Nephrology (AREA)
- Pain & Pain Management (AREA)
- Transplantation (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IN288KO2012 | 2012-03-14 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NI201400107A true NI201400107A (es) | 2014-11-26 |
Family
ID=47997632
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NI201400108A NI201400108A (es) | 2012-03-14 | 2014-09-11 | Compuestos de heterociclilo |
| NI201400107A NI201400107A (es) | 2012-03-14 | 2014-09-11 | Compuestos de heterociclilo como inhibidores de mek |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NI201400108A NI201400108A (es) | 2012-03-14 | 2014-09-11 | Compuestos de heterociclilo |
Country Status (35)
Families Citing this family (52)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2012088266A2 (en) | 2010-12-22 | 2012-06-28 | Incyte Corporation | Substituted imidazopyridazines and benzimidazoles as inhibitors of fgfr3 |
| JP6431770B2 (ja) | 2012-03-14 | 2018-11-28 | ルピン・リミテッド | Ｍｅｋインヒビターとしてのヘテロシクリル化合物 |
| UA125503C2 (uk) | 2012-06-13 | 2022-04-13 | Інсайт Холдинґс Корпорейшн | Заміщені трициклічні сполуки як інгібітори fgfr |
| US9388185B2 (en) | 2012-08-10 | 2016-07-12 | Incyte Holdings Corporation | Substituted pyrrolo[2,3-b]pyrazines as FGFR inhibitors |
| US9266892B2 (en) | 2012-12-19 | 2016-02-23 | Incyte Holdings Corporation | Fused pyrazoles as FGFR inhibitors |
| MY181497A (en) | 2013-04-19 | 2020-12-23 | Incyte Holdings Corp | Bicyclic heterocycles as fgfr inhibitors |
| CA2927635C (en) * | 2013-10-25 | 2021-07-20 | Shanghai Hengrui Pharmaceutical Co., Ltd. | Pyridic ketone derivatives, method of preparing same, and pharmaceutical application thereof |
| WO2016009306A1 (en) * | 2014-07-15 | 2016-01-21 | Lupin Limited | Heterocyclyl compounds as mek inhibitors |
| WO2016035008A1 (en) * | 2014-09-04 | 2016-03-10 | Lupin Limited | Pyridopyrimidine derivatives as mek inhibitors |
| US10851105B2 (en) | 2014-10-22 | 2020-12-01 | Incyte Corporation | Bicyclic heterocycles as FGFR4 inhibitors |
| MA41551A (fr) | 2015-02-20 | 2017-12-26 | Incyte Corp | Hétérocycles bicycliques utilisés en tant qu'inhibiteurs de fgfr4 |
| CR20170390A (es) | 2015-02-20 | 2017-10-23 | Incyte Holdings Corp | Heterociclos biciclicos como inhibidores de fgfr |
| US9580423B2 (en) | 2015-02-20 | 2017-02-28 | Incyte Corporation | Bicyclic heterocycles as FGFR4 inhibitors |
| EP3878850A1 (en) | 2016-12-22 | 2021-09-15 | Boehringer Ingelheim International GmbH | Novel benzylamino substituted quinazolines and derivatives as sos1 inhibitors |
| AR111960A1 (es) | 2017-05-26 | 2019-09-04 | Incyte Corp | Formas cristalinas de un inhibidor de fgfr y procesos para su preparación |
| DK3728254T3 (da) * | 2017-12-21 | 2023-06-06 | Boehringer Ingelheim Int | Benzylamin-substituerede pyridopyrimidinoner og derivater som sos1-inhibitorer |
| BR112020022392A2 (pt) | 2018-05-04 | 2021-02-02 | Incyte Corporation | formas sólidas de um inibidor de fgfr e processos para preparação das mesmas |
| PE20210919A1 (es) | 2018-05-04 | 2021-05-19 | Incyte Corp | Sales de un inhibidor de fgfr |
| US11628162B2 (en) | 2019-03-08 | 2023-04-18 | Incyte Corporation | Methods of treating cancer with an FGFR inhibitor |
| JP2022526713A (ja) | 2019-03-21 | 2022-05-26 | オンクセオ | がんの処置のための、キナーゼ阻害剤と組み合わせたＤｂａｉｔ分子 |
| BR112021024532A2 (pt) | 2019-06-19 | 2022-05-24 | Boehringer Ingelheim Int | Terapia combinada anticâncer |
| US11591329B2 (en) | 2019-07-09 | 2023-02-28 | Incyte Corporation | Bicyclic heterocycles as FGFR inhibitors |
| CN114502169A (zh) * | 2019-07-30 | 2022-05-13 | 埃德文斯公司 | 用于治疗中风的mek抑制剂 |
| EP3797899A1 (de) | 2019-09-27 | 2021-03-31 | Primetals Technologies Austria GmbH | Vorrichtung und verfahren zum erkennen von einer bewegung eines körpers in einer industrieanlage |
| US12122767B2 (en) | 2019-10-01 | 2024-10-22 | Incyte Corporation | Bicyclic heterocycles as FGFR inhibitors |
| GEP20247679B (en) | 2019-10-14 | 2024-10-10 | Incyte Corp | Bicyclic heterocycles as fgfr inhibitors |
| WO2021076728A1 (en) | 2019-10-16 | 2021-04-22 | Incyte Corporation | Bicyclic heterocycles as fgfr inhibitors |
| KR20220098759A (ko) | 2019-11-08 | 2022-07-12 | 인쎄름 (엥스띠뛰 나씨오날 드 라 쌍떼 에 드 라 흐쉐르슈 메디깔) | 키나제 억제제에 대해 내성을 획득한 암의 치료 방법 |
| PE20221504A1 (es) | 2019-12-04 | 2022-09-30 | Incyte Corp | Derivados de un inhibidor de fgfr |
| JP7720840B2 (ja) | 2019-12-04 | 2025-08-08 | インサイト・コーポレイション | Ｆｇｆｒ阻害剤としての三環式複素環 |
| WO2021146424A1 (en) | 2020-01-15 | 2021-07-22 | Incyte Corporation | Bicyclic heterocycles as fgfr inhibitors |
| WO2021148581A1 (en) | 2020-01-22 | 2021-07-29 | Onxeo | Novel dbait molecule and its use |
| US20230212164A1 (en) | 2020-06-02 | 2023-07-06 | Boehringer Ingelheim International Gmbh | Annulated 2-amino-3-cyano thiophenes and derivatives for the treatment of cancer |
| TWI825637B (zh) * | 2021-03-31 | 2023-12-11 | 美商輝瑞股份有限公司 | 啶－１，６（２ｈ，７ｈ）－二酮 |
| CN117479942A (zh) | 2021-04-09 | 2024-01-30 | 勃林格殷格翰国际有限公司 | 抗癌疗法 |
| TW202304459A (zh) | 2021-04-12 | 2023-02-01 | 美商英塞特公司 | 包含ｆｇｆｒ抑制劑及ｎｅｃｔｉｎ－４靶向劑之組合療法 |
| EP4323066A1 (en) * | 2021-04-16 | 2024-02-21 | Ikena Oncology, Inc. | Mek inhibitors and uses thereof |
| JP2024521788A (ja) | 2021-05-27 | 2024-06-04 | ミラティ セラピューティクス， インコーポレイテッド | 併用療法 |
| CA3220155A1 (en) | 2021-06-09 | 2022-12-15 | Incyte Corporation | Tricyclic heterocycles as fgfr inhibitors |
| TW202313611A (zh) | 2021-06-09 | 2023-04-01 | 美商英塞特公司 | 作為ｆｇｆｒ抑制劑之三環雜環 |
| CN118613485A (zh) | 2021-12-01 | 2024-09-06 | 勃林格殷格翰国际有限公司 | 用于治疗癌症的环状2-氨基-3-氰基噻吩及衍生物 |
| EP4441050A1 (en) | 2021-12-01 | 2024-10-09 | Boehringer Ingelheim International GmbH | Annulated 2-amino-3-cyano thiophenes and derivatives for the treatment of cancer |
| EP4441054A1 (en) | 2021-12-01 | 2024-10-09 | Boehringer Ingelheim International GmbH | Annulated 2-amino-3-cyano thiophenes and derivatives for the treatment of cancer |
| WO2023099620A1 (en) | 2021-12-01 | 2023-06-08 | Boehringer Ingelheim International Gmbh | Kras degrading compounds comprising annulated 2-amino-3-cyano thiophenes |
| JP2024543967A (ja) | 2021-12-01 | 2024-11-26 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | ガン処置のための環化２－アミノ－３－シアノチオフェン及び誘導体 |
| CN114456166B (zh) * | 2022-03-30 | 2023-06-16 | 沈阳药科大学 | 5-取代氨基-3-甲基吡啶并[2,3-d]嘧啶类化合物及其制备与应用 |
| CN114573581B (zh) * | 2022-03-30 | 2023-09-01 | 沈阳药科大学 | 5-取代氨基-1,3-二取代苯基吡啶并[2,3-d]嘧啶类化合物及其制备与应用 |
| CN114605408B (zh) * | 2022-03-30 | 2023-06-16 | 沈阳药科大学 | 5-羟基-1,3-二取代苯基吡啶并[2,3-d]嘧啶类化合物及其制法和应用 |
| CN114573582B (zh) * | 2022-03-30 | 2023-06-16 | 沈阳药科大学 | 1,2,3,4-四氢吡啶并[2,3-d]嘧啶类化合物及其制备方法和应用 |
| TW202404581A (zh) | 2022-05-25 | 2024-02-01 | 美商醫肯納腫瘤學公司 | Ｍｅｋ抑制劑及其用途 |
| WO2024246099A1 (en) | 2023-05-30 | 2024-12-05 | Boehringer Ingelheim International Gmbh | Spirocyclic annulated 2-amino-3-cyano thiophenes and derivatives for the treatment of cancer |
| WO2025073765A1 (en) | 2023-10-03 | 2025-04-10 | Institut National de la Santé et de la Recherche Médicale | Methods of prognosis and treatment of patients suffering from melanoma |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4235871A (en) | 1978-02-24 | 1980-11-25 | Papahadjopoulos Demetrios P | Method of encapsulating biologically active materials in lipid vesicles |
| US4501728A (en) | 1983-01-06 | 1985-02-26 | Technology Unlimited, Inc. | Masking of liposomes from RES recognition |
| US5019369A (en) | 1984-10-22 | 1991-05-28 | Vestar, Inc. | Method of targeting tumors in humans |
| US4837028A (en) | 1986-12-24 | 1989-06-06 | Liposome Technology, Inc. | Liposomes with enhanced circulation time |
| UA72612C2 (en) * | 2000-07-06 | 2005-03-15 | Pyrido[2.3-d]pyrimidine and pyrimido[4.5-d]pyrimidine nucleoside analogues, prodrugs and method for inhibiting growth of neoplastic cells | |
| US6825180B2 (en) * | 2001-05-18 | 2004-11-30 | Cell Therapeutics, Inc. | Pyridopyrimidine compounds and their uses |
| GB0129099D0 (en) | 2001-12-05 | 2002-01-23 | Astrazeneca Ab | Chemical compounds |
| PL218692B1 (pl) * | 2002-01-22 | 2015-01-30 | Warner Lambert Co | Podstawiony 2-(pirydyn-2-yloamino)pirydo[2,3-d]pirymidyn-7-on oraz jego zastosowanie do leczenia zaburzenia lub stanu spowodowanego nieprawidłową proliferacją komórek |
| US7235537B2 (en) | 2002-03-13 | 2007-06-26 | Array Biopharma, Inc. | N3 alkylated benzimidazole derivatives as MEK inhibitors |
| BRPI0416692A (pt) | 2003-11-19 | 2007-01-30 | Array Biopharma Inc | inibidores heterocìclicos de mek e métodos de emprego destes |
| PL1761528T3 (pl) * | 2004-06-11 | 2008-05-30 | Japan Tobacco Inc | Pochodne 5-amino-2,4,7-triokso-3,4,7,8-tetrahydro-2H-pirydo[2,3-D]pirymidyny i związki pokrewne do leczenia raka |
| US7378423B2 (en) | 2004-06-11 | 2008-05-27 | Japan Tobacco Inc. | Pyrimidine compound and medical use thereof |
| BRPI0925050A2 (pt) | 2009-04-21 | 2015-08-04 | Novartis Ag | Compostos heterocíclicos como inibidores de mek |
| JP6431770B2 (ja) | 2012-03-14 | 2018-11-28 | ルピン・リミテッド | Ｍｅｋインヒビターとしてのヘテロシクリル化合物 |
-
2013
- 2013-03-11 JP JP2014561564A patent/JP6431770B2/ja active Active
- 2013-03-11 AU AU2013234009A patent/AU2013234009B2/en active Active
- 2013-03-11 KR KR1020197017334A patent/KR102240101B1/ko not_active Expired - Fee Related
- 2013-03-11 GE GEAP201313596A patent/GEP201706774B/en unknown
- 2013-03-11 PL PL13712929T patent/PL2834237T3/pl unknown
- 2013-03-11 PE PE2014001399A patent/PE20141973A1/es active IP Right Grant
- 2013-03-11 CN CN201380023296.2A patent/CN104271577A/zh active Pending
- 2013-03-11 CA CA2865167A patent/CA2865167C/en not_active Expired - Fee Related
- 2013-03-11 CU CUP2014000109A patent/CU24335B1/es unknown
- 2013-03-11 UA UAA201411014A patent/UA114907C2/uk unknown
- 2013-03-11 MA MA37405A patent/MA37405A1/fr unknown
- 2013-03-11 KR KR1020147028557A patent/KR20140138911A/ko not_active Ceased
- 2013-03-11 PE PE2014001400A patent/PE20141974A1/es active IP Right Grant
- 2013-03-11 GE GEAP201313595A patent/GEP201706671B/en unknown
- 2013-03-11 KR KR1020147028556A patent/KR20140138910A/ko not_active Ceased
- 2013-03-11 NZ NZ629442A patent/NZ629442A/en not_active IP Right Cessation
- 2013-03-11 CU CUP2014000110A patent/CU24272B1/xx unknown
- 2013-03-11 US US14/385,106 patent/US9573944B2/en active Active
- 2013-03-11 ES ES13712929T patent/ES2684517T3/es active Active
- 2013-03-11 DK DK13711973.1T patent/DK2834236T3/da active
- 2013-03-11 MX MX2014010925A patent/MX355526B/es active IP Right Grant
- 2013-03-11 US US14/385,092 patent/US9428499B2/en active Active
- 2013-03-11 CA CA2865164A patent/CA2865164C/en active Active
- 2013-03-11 MX MX2014010928A patent/MX355474B/es active IP Right Grant
- 2013-03-11 MX MX2018003665A patent/MX366426B/es unknown
- 2013-03-11 MY MYPI2014002638A patent/MY175950A/en unknown
- 2013-03-11 JP JP2014561567A patent/JP6093384B2/ja active Active
- 2013-03-11 EP EP13712929.2A patent/EP2834237B1/en active Active
- 2013-03-11 MA MA37400A patent/MA37400B1/fr unknown
- 2013-03-11 ES ES13711973T patent/ES2741896T3/es active Active
- 2013-03-11 AP AP2014008008A patent/AP3834A/en active
- 2013-03-11 MY MYPI2014002639A patent/MY174188A/en unknown
- 2013-03-11 EA EA201491671A patent/EA029768B1/ru unknown
- 2013-03-11 WO PCT/IB2013/051915 patent/WO2013136254A1/en not_active Ceased
- 2013-03-11 EP EP13711973.1A patent/EP2834236B1/en active Active
- 2013-03-11 IN IN1754MUN2014 patent/IN2014MN01754A/en unknown
- 2013-03-11 TR TR2018/11976T patent/TR201811976T4/tr unknown
- 2013-03-11 AU AU2013234014A patent/AU2013234014B2/en not_active Ceased
- 2013-03-11 NZ NZ629432A patent/NZ629432A/en unknown
- 2013-03-11 AP AP2014008009A patent/AP3859A/en active
- 2013-03-11 SG SG11201405007QA patent/SG11201405007QA/en unknown
- 2013-03-11 EA EA201491672A patent/EA028232B1/ru unknown
- 2013-03-11 KR KR1020197024543A patent/KR102241111B1/ko active Active
- 2013-03-11 CN CN201710823363.9A patent/CN107698585A/zh active Pending
- 2013-03-11 UA UAA201411011A patent/UA114906C2/uk unknown
- 2013-03-11 CN CN201810086896.8A patent/CN108383836B/zh active Active
- 2013-03-11 BR BR112014022713-6A patent/BR112014022713B1/pt active IP Right Grant
- 2013-03-11 IN IN1755MUN2014 patent/IN2014MN01755A/en unknown
- 2013-03-11 WO PCT/IB2013/051908 patent/WO2013136249A1/en not_active Ceased
- 2013-03-11 DK DK13712929.2T patent/DK2834237T3/en active
- 2013-03-11 CN CN201380014210.XA patent/CN104203947A/zh active Pending
- 2013-03-11 SG SG11201405006PA patent/SG11201405006PA/en unknown
-
2014
- 2014-08-18 TN TNP2014000357A patent/TN2014000357A1/fr unknown
- 2014-08-18 TN TNP2014000356A patent/TN2014000356A1/fr unknown
- 2014-08-22 ZA ZA2014/06186A patent/ZA201406186B/en unknown
- 2014-09-09 IL IL234560A patent/IL234560A/en active IP Right Grant
- 2014-09-09 IL IL234559A patent/IL234559A/en active IP Right Grant
- 2014-09-10 DO DO2014000204A patent/DOP2014000204A/es unknown
- 2014-09-10 DO DO2014000203A patent/DOP2014000203A/es unknown
- 2014-09-11 NI NI201400108A patent/NI201400108A/es unknown
- 2014-09-11 NI NI201400107A patent/NI201400107A/es unknown
- 2014-09-12 PH PH12014502040A patent/PH12014502040B1/en unknown
- 2014-09-12 PH PH12014502041A patent/PH12014502041A1/en unknown
- 2014-09-12 CL CL2014002411A patent/CL2014002411A1/es unknown
- 2014-09-12 GT GT201400196A patent/GT201400196A/es unknown
- 2014-09-12 GT GT201400195A patent/GT201400195A/es unknown
- 2014-09-12 CL CL2014002412A patent/CL2014002412A1/es unknown
- 2014-10-06 CO CO14221195A patent/CO7160029A2/es unknown
- 2014-10-06 CR CR20140463A patent/CR20140463A/es unknown
- 2014-10-06 CO CO14221191A patent/CO7170131A2/es unknown
- 2014-10-06 CR CR20140464A patent/CR20140464A/es unknown
-
2016
- 2016-07-25 US US15/218,980 patent/US9555035B2/en active Active
- 2016-12-22 US US15/388,327 patent/US9969731B2/en active Active
-
2017
- 2017-01-06 US US15/400,627 patent/US9827247B2/en active Active
- 2017-01-25 AU AU2017200493A patent/AU2017200493B2/en active Active
-
2018
- 2018-04-12 AU AU2018202568A patent/AU2018202568B2/en active Active
- 2018-05-01 JP JP2018088389A patent/JP6630771B2/ja active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NI201400107A (es) | Compuestos de heterociclilo como inhibidores de mek | |
| ECSP19011216A (es) | Inhibidores de piridopyrimdinona cdk2/4/6 | |
| ECSP14013215A (es) | Compuestos novedosos | |
| CR20140399A (es) | Pirrolidina-2-carboxamidas sustituidas | |
| MX2016014547A (es) | Compuestos para tratar atrofia muscular espinal. | |
| DOP2015000158A (es) | Inhibidores de prmt5 y sus usos | |
| UY34917A (es) | Inhibidores de la producción de leucotrieno-a4-hidrolasa (lta4h), composiciones farmacéuticas que los contienen y proceso para su preparación | |
| CR20150472A (es) | USO DE DERIVADOS DE PIRAZOLOPIRIMIDINA PARA EL TRATAMIENTO DE TRANSTORNOS RELACIONADOS CON LA PI3Kd | |
| MX382991B (es) | Inhibidores de la arginina metiltransferasa y usos de los mismos. | |
| IN2014MN02598A (show.php) | ||
| ECSP16074478A (es) | Compuestos novedosos | |
| UY33440A (es) | ?compuestos pirimidinílicos para uso como inhibidores de atr?. | |
| CO6771439A2 (es) | Inhibidores de benzodioxano de la producción de leucotrieno | |
| ECSP17069696A (es) | Compuestos novedosos | |
| NI201600014A (es) | Compuestos y composiciones como inhibidores de la mek. | |
| MX386584B (es) | Composiciones de liberación retardada de linaclotida. | |
| UY34955A (es) | 4-metil-2,3,5,9,9b-pentaaza-ciclopenta[a]naftalenos | |
| DOP2018000062A (es) | Piridinona dicaboxamidas para uso como inhibidores de bromodominio | |
| NI201500096A (es) | Compuesto químicos | |
| UY36110A (es) | Inhibidores de quinasa relacionados con tropomiosina | |
| UY36228A (es) | Derivados de heteroarilo como inhibidores de aldosterona sintasa (cyp11b2) y composiciones farmacéuticas que los contienen | |
| UY33490A (es) | Ésteres de quinolina nuevos útiles para el tratamiento de trastornos cutáneos. | |
| EA201600394A1 (ru) | Трициклические соединения пиперидина | |
| ECSP16074482A (es) | Ciclopentanos, tetrahidrofuranos y pirrolidinas sustituidas como antagonistas del receptor de orexina | |
| EA201590656A1 (ru) | Азаиндолины |